China Preclinical Cro Market Size & Outlook, 2023-2030
China preclinical cro market, 2018-2030 (US$M)
Related Markets
China preclinical cro market highlights
- The China preclinical cro market generated a revenue of USD 292.8 million in 2023 and is expected to reach USD 654.3 million by 2030.
- The China market is expected to grow at a CAGR of 12.2% from 2024 to 2030.
- In terms of segment, toxicology testing was the largest revenue generating service in 2023.
- Bioanalysis and DMPK studies is the most lucrative service segment registering the fastest growth during the forecast period.
Preclinical cro market data book summary
| Market revenue in 2023 | USD 292.8 million |
| Market revenue in 2030 | USD 654.3 million |
| Growth rate | 12.2% (CAGR from 2023 to 2030) |
| Largest segment | Toxicology testing |
| Fastest growing segment | Bioanalysis and DMPK studies |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Bioanalysis and DMPK studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology |
| Key market players worldwide | Eurofins Scientific SE, Icon PLC, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Thermo Fisher Scientific Inc, Intertek Group PLC, Labcorp Holdings Inc, Crown Bioscience, SGA |
Other key industry trends
- In terms of revenue, China accounted for 5.1% of the global preclinical cro market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China preclinical cro market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 654.3 million by 2030.
Toxicology testing was the largest segment with a revenue share of 22.58% in 2023. Horizon Databook has segmented the China preclinical cro market based on bioanalysis and dmpk studies, toxicology testing, compound management, chemistry, safety pharmacology covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the lucrative preclinical trial markets owing to its skilled professionals, cost efficiency, and growing pharmaceutical industry. The country has witnessed positive growth in global preclinical trials conducted in 2023 and is expected to grow at a significant rate over the forecast period. The primary reason for outsourcing preclinical services in China is the higher cost efficiency provided by Chinese CROs as compared to the U.S. and Europe.
Most of life sciences companies outsource their preclinical trials to China due to higher cost efficiency. These advantages are expected to contribute to the growth of preclinical trials outsourcing in the country. However, quality issues and lack of standardization in preclinical trials conducted in this region may limit the market growth over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Preclinical CRO Market Scope
Preclinical CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China preclinical cro market size, by service, 2018-2030 (US$M)
China Preclinical CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
